{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:21:51Z","timestamp":1791195711581,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.ejpb.2011.10.003","type":"journal-article","created":{"date-parts":[[2011,10,15]],"date-time":"2011-10-15T08:01:57Z","timestamp":1318665717000},"page":"54-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Inhalable dry-emulsion formulation of cyclosporine A with improved anti-inflammatory effects in experimental asthma\/COPD-model rats"],"prefix":"10.1016","volume":"80","author":[{"given":"Satomi","family":"Onoue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Kojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Mizumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuo","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2011.10.003_b0005","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/0091-6749(92)90331-U","article-title":"Is there a role for cyclosporine in asthma?","volume":"89","author":"Calderon","year":"1992","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejpb.2011.10.003_b0010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/03639040601155665","article-title":"Cyclosporine A: a review of current oral and intravenous delivery systems","volume":"33","author":"Beauchesne","year":"2007","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2011.10.003_b0015","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/0140-6736(92)91646-P","article-title":"Trial of cyclosporin in corticosteroid-dependent chronic severe asthma","volume":"339","author":"Alexander","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.ejpb.2011.10.003_b0020","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2125.1991.tb05540.x","article-title":"Cyclosporin metabolism by the gastrointestinal mucosa","volume":"31","author":"Tjia","year":"1991","journal-title":"Brit. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2011.10.003_b0025","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1177\/009127000004001106","article-title":"Pharmacokinetics, pharmacodynamics, and safety of inhaled cyclosporin A (ADI628) after single and repeated administration in healthy male and female subjects and asthmatic patients","volume":"40","author":"Rohatagi","year":"2000","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2011.10.003_b0030","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/10611869909085494","article-title":"Nebulizer-compatible liquid formulations for aerosol pulmonary delivery of hydrophobic drugs: glucocorticoids and cyclosporine","volume":"7","author":"Klyashchitsky","year":"1999","journal-title":"J. Drug Target"},{"key":"10.1016\/j.ejpb.2011.10.003_b0035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jconrel.2009.04.014","article-title":"In vitro and in vivo characterization on amorphous solid dispersion of cyclosporine A for inhalation therapy","volume":"138","author":"Onoue","year":"2009","journal-title":"J. Control Release"},{"key":"10.1016\/j.ejpb.2011.10.003_b0040","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.drudis.2007.09.005","article-title":"Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs","volume":"12","author":"Vasconcelos","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejpb.2011.10.003_b0045","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ijpharm.2008.07.019","article-title":"Physicochemical and pharmacokinetic characterization of water-soluble Coenzyme Q(10) formulations","volume":"363","author":"Hatanaka","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2011.10.003_b0050","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ejps.2009.04.002","article-title":"Novel dry powder formulation of ovalbumin for development of COPD-like animal model: Physicochemical characterization and biomarker profiling in rats","volume":"37","author":"Misaka","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2011.10.003_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2009.03.020","article-title":"Characterization of a new inhalable thymopentin formulation","volume":"375","author":"Wang","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2011.10.003_b0060","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/jps.20523","article-title":"Quantitative determination of amorphous cyclosporine in crystalline cyclosporine samples by Fourier transform infrared spectroscopy","volume":"95","author":"Bertacche","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2011.10.003_b0065","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijpharm.2010.08.007","article-title":"Improved dissolution and pharmacokinetic behavior of cyclosporine A using high-energy amorphous solid dispersion approach","volume":"399","author":"Onoue","year":"2010","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ejpb.2011.10.003_b0070","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0928-0987(03)00134-9","article-title":"Spray-dried redispersible oil-in-water emulsion to improve oral bioavailability of poorly soluble drugs","volume":"19","author":"Dollo","year":"2003","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2011.10.003_b0075","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1517\/13543776.13.9.1333","article-title":"Inhalation drug delivery devices and emerging technologies","volume":"13","author":"Chan","year":"2003","journal-title":"Expert Opin. Ther. Patents"},{"key":"10.1016\/j.ejpb.2011.10.003_b0080","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0378-5173(03)00156-X","article-title":"The influence of carrier and drug morphology on drug delivery from dry powder formulations","volume":"257","author":"Larhrib","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2011.10.003_b0085","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cca.2005.06.008","article-title":"Laboratory markers for COPD in \u201csusceptible\u201d smokers","volume":"364","author":"Tzortzaki","year":"2006","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ejpb.2011.10.003_b0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00580-006-0655-x","article-title":"Total and differential leucocyte counts in rat and mouse bronchoalveolar lavage fluids using the Sysmex XT-2000iV","volume":"16","author":"Mathers","year":"2007","journal-title":"Comp. Clin. Pathol."},{"key":"10.1016\/j.ejpb.2011.10.003_b0095","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1124\/pr.56.4.2","article-title":"Mediators of chronic obstructive pulmonary disease","volume":"56","author":"Barnes","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejpb.2011.10.003_b0100","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1398-9995.1991.tb00590.x","article-title":"Cyclosporin for steroid-dependent asthma","volume":"46","author":"Szczeklik","year":"1991","journal-title":"Allergy"},{"key":"10.1016\/j.ejpb.2011.10.003_b0105","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1517\/13543776.18.4.429","article-title":"Dry powder inhalation systems for pulmonary delivery of therapeutic peptides and proteins","volume":"18","author":"Onoue","year":"2008","journal-title":"Expert Opin. Ther. Patents"},{"key":"10.1016\/j.ejpb.2011.10.003_b0110","first-page":"437","article-title":"The effect of omega-3 fatty acids and vitamin E on the nephrotoxicity of cyclosporin A in hereditary hypertriglyceridemic rats","volume":"48","author":"Bohdanecka","year":"1999","journal-title":"Physiol. Res."},{"key":"10.1016\/j.ejpb.2011.10.003_b0115","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0039-6060(05)80349-6","article-title":"Efficacy of inhaled cyclosporine in lung transplant recipients with refractory rejection: correlation of intragraft cytokine gene expression with pulmonary function and histologic characteristics","volume":"118","author":"Keenan","year":"1995","journal-title":"Surgery"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641111002980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641111002980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:28:49Z","timestamp":1760545729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641111002980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0939641111002980"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2011.10.003","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhalable dry-emulsion formulation of cyclosporine A with improved anti-inflammatory effects in experimental asthma\/COPD-model rats","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2011.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}